Newfeed

FDA ODAC unanimously votes 11 to 0 supporting favorable risk-benefit assessment of CARVYKTI® based on results from the Phase 3 CARTITUDE-4 study RARITAN, N.J., March 15, 2024  /PRNewswire/ — Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) Oncologic Drug

Magazine made for you.

Featured:

No posts were found for provided query parameters.

Elsewhere: